Dear Ms. Petraglia:

Please refer to your supplemental new drug applications dated September 24, 2004, received September 27, 2004 (NDA 21-223/S-009) and November 22, 2004, received November 23, 2004 (NDA 21-223/S-010), submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Zometa (zoledronic acid) Injection.

These "Changes Being Effected" supplemental new drug applications provide for a new subsection entitled Osteonecrosis of the Jaw in the Precautions section of the package insert, and updated information in the Renal Insufficiency subsection of the Precautions section, the Adverse Reaction subsection of the Warnings section, and the DOSAGE AND ADMINISTRATION section concerning dosing with pre-existing renal insufficiency.

We have completed our review of these supplemental applications. They are approved, effective on the date of this letter, for use as recommended in the final printed labeling (FPL) submitted on November 22, 2004.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Randy Hedin, R.Ph., Senior Regulatory Management Officer, at (301) 827-6392.

Sincerely,

{See appended electronic signature page}

David G. Orloff, M.D.
Director
Division of Metabolic and Endocrine Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosure
This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.

/s/
---------------------
David Orloff
1/31/05 02:58:28 PM